Media Release

Basel, 08 September 2015

Roche to present data from 15 medicines across its portfolio of cancer immunotherapy and targeted medicines during the 2015 European Cancer Congress

  • Pivotal results for atezolizumab in urothelial bladder cancer and non-small cell lung cancer
  • Studies supporting regulatory discussions for three new medicines
  • Additional data from Roche’s early cancer immunotherapy pipeline in solid tumours

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that data from 138 abstracts will be presented at this year’s European Cancer Congress (ECC) from 25–29 September in Vienna, Austria. Results will be presented from several clinical studies that are supporting ongoing regulatory discussions for three investigational medicines across specific types of lung, bladder and skin cancer (alectinib, atezolizumab and cobimetinib, which recently received its first approval in Switzerland where it is marketed as Cotellic®). Building on its large portfolio of approved cancer medicines, these regulatory discussions represent significant progress for Roche’s pipeline in the fields of cancer immunotherapy and targeted medicines.

"With our targeted medicines, cancer immunotherapies and the combination potential in our portfolio, we are committed to setting new standards for treating people with cancer," said Sandra Horning, M.D., Roche’s Chief Medical Officer and Head of Global Product Development. "At the 2015 European Cancer Congress, new data will be presented for three investigational medicines that we hope will be approved within the next year, including atezolizumab for people with PD-L1 expressing lung and bladder cancers."

In addition to data for alectinib, atezolizumab and cobimetinib, results will be presented across multiple tumour types from Roche’s cancer immunotherapy and targeted medicines pipeline including CEA-IL2v (RG7813), IDO Inhibitor (GDC-0919) and vanucizumab (anti-Ang2/VEGF, RG7221). The table below contains key abstracts featuring Roche medicines, including late breaking abstracts that will be presented during the Congress.

Follow Roche on Twitter via @Roche and keep up to date with the 2015 European Cancer Congress news and updates by using the hashtag #ECC2015.

Overview of key abstracts featuring Roche medicines

MedicineAbstract titleAbstract number

atezolizumab (MPDL3280A; anti-PDL1)


POPLAR: Atezolizumab monotherapy vs docetaxel in 2L/3L non-small cell lung cancer: Primary analyses for efficacy, safety and predictive biomarkers from a randomized phase II study (POPLAR). J. Vansteenkiste et al.

#14LBA (Proffered Paper Session)

Sunday September 27

09:15 CET

BIRCH: Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1–selected non-small cell lung cancer (NSCLC). Benjamin Besse et al.

#16LBA (Proffered Paper Session)

Sunday September 27

IMvigor210: Atezolizumab in patients (pts) with locally-advanced or metastatic urothelial carcinoma (mUC): Results from a pivotal multicenter phase II study (IMvigor 210). J. Rosenberg et al.

#21LBA (Proffered Paper Session)

Sunday September 27

10:40 CET

Safety, activity and biomarkers of atezolizumab (MPDL3280A) with platinum-based chemotherapy (chemo) in non-small cell lung cancer (NSCLC): A Phase Ib study. G. Giaccone et al.

#513 (Poster Session)

Saturday September 26

16:45 CET

NSCLC with high PD-L1 expression on tumor cells or tumor-infiltrating immune cells represents distinct cancer subtypes. P. Schmid et al.

#3017 (Poster Discussion)

Sunday September 27

08:00 CET

alectinibUpdated efficacy and safety results from a global phase 2, open-label, single-arm study (NP28673) of alectinib in crizotinib-refractory ALK+ non-small-cell lung cancer (NSCLC). F. Barlesi et al.

#3101 (Poster Session)

Sunday 27 September

09:15 CET

cobimetinib (Cotellic)Impact of baseline genetic heterogeneities on progression-free survival (PFS) in patients (pts) with advanced BRAFV600-mutated melanoma treated with cobimetinib (COBI) + vemurafenib (VEM) in the phase 3 coBRIM study. G. McArthur et al.

#25LBA (Proffered Paper Session)

Sunday 27 September

12:10 CET

CEA-IL2v (RG7813)


Clinical evidence of intra-tumoral immune activation and tumor targeting with RG7813, a CEA-targeted engineered IL-2 immunocytokine. J. Tabernero et al.

#505 (Proffered Paper Session)

Sunday 27 September

18:30 CET

IDO Inhibitor



Phase 1a study of the safety, pharmacokinetics, and pharmacodynamics of GDC-0919 in patients with recurrent/advanced solid tumors. A. Nayak et al.

#346 (Poster Session)

Sunday 27 September

16:45 CET

vanucizumab (anti-Ang2/VEGF, RG7221)


Vanucizumab reduces vessel permeability, perfusion and cellular density of tumor lesions in cancer patients as measured by DCE-MRI and DW-MRI. T. Nayak et al.

#304 (Proffered Paper Session)

Saturday 26 September

11:35 CET

About Roche in personalised cancer immunotherapy

For more than 30 years, Roche has been developing medicines with the goal to redefine treatment in oncology. Today, we’re investing more than ever to bring personalised cancer immunotherapy (PCI) to people with cancer. The goal of PCI is to provide each person with a treatment tailored to harness his or her own immune system to fight cancer. Roche is studying more than 20 investigational medicines, seven of which are in clinical trials. In every study we are evaluating biomarkers to identify which people may be appropriate candidates for our medicines.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy. In 2014, the Roche Group employed 88,500 people worldwide, invested 8.9 billion Swiss francs in R&D and posted sales of 47.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit

All trademarks used or mentioned in this release are protected by law.